From: Nino Patarashvili
Sent: Thursday, April 8, 2021 20:24
To: Jelena Lukic ; Nino Kvernadze ; Darejan Kapanadze ; David Jijelava
Cc: Tamar Gabunia ; Volkan Cetinkaya ; Giorgi Kobaladze ; Nino V. Moroshkina ; Lia Tavadze ; Beka Jakeli
Subject: RE: Georgia COVID-19 project additional financing for vaccines - WB comments on SEP

From: Jelena Lukic <jlukic@worldbank.org>
Sent: 8 April, 2021 20:25
To: Nino Patarashvili <npatarashvili@moh.gov.ge>; Nino Kvernadze <ninokvernadze@moh.gov.ge>; Darejan Kapanadze <dkapanadze@worldbank.org>; David Jijelava <djijelava@worldbank.org>
Cc: Tamar Gabunia <tgabunia@moh.gov.ge>; Volkan Cetinkaya <vcetinkaya@worldbank.org>; Giorgi Kobaladze <gkobaladze@moh.gov.ge>; Nino V. Moroshkina <nmoroshkina@worldbank.org>; Lia Tavadze <ltavadze@moh.gov.ge>; Beka Jakeli <bjakeli@moh.gov.ge>
Subject: RE: Georgia COVID-19 project additional financing for vaccines - WB comments on SEP

From: Nino Patarashvili <npatarashvili@moh.gov.ge>
Sent: Thursday, April 8, 2021 4:07 PM
To: Jelena Lukic <jlukic@worldbank.org>; Nino Kvernadze <ninokvernadze@moh.gov.ge>; Darejan Kapanadze <dkapanadze@worldbank.org>; David Jijelava <djijelava@worldbank.org>
Cc: tgabunia@moh.gov.ge; Volkan Cetinkaya <vcetinkaya@worldbank.org>; Giorgi Kobaladze <gkobaladze@moh.gov.ge>; Nino V. Moroshkina <nmoroshkina@worldbank.org>; Lia Tavadze <ltavadze@moh.gov.ge>; Beka Jakeli <bjakeli@moh.gov.ge>
Subject: RE: Georgia COVID-19 project additional financing for vaccines - WB comments on SEP

Dear Team,

Please find enclosed first drafts of documents for additional Covid-19 vaccine financing.

Kind regards,

Nino Kvernadze

Dear Nino, dear Colleagues,

As a follow up to our previous exchange, I am sharing the following documents which may be helpful when revising the ESMF and SEP to adjust for the vaccine Additional Financing.

1)     Template for the ESMF for vaccines projects – please, see the text marked in red – these areas need to be addressed and revised in the existing COVID ESMF

2)     Example of SEP for a vaccine project – please, treat it only as example, so you can see how can the existing COVID SEP be revised to adjust fo the vaccine component. SEP should specifically address the issues that  vaccines reach out to disadvantaged and vulnerable groups after identifying their barriers to access. Stakeholder engagement is key to communicating the principles on fair, equitable and inclusive access and allocation of vaccines, reaching out to disadvantaged and vulnerable groups, overcoming demand-side barriers to access (such as mistrust of vaccines, stigma, cultural hesitancy), and creating accountability against misallocation, discrimination and corruption. These issues should be addressed in detail in a Stakeholder Engagement Plan (SEP), and referenced in the ESMF.

The attached Georgia COVID-19 Vaccine deployment plan includes some critical points which should be included/referenced both in the ESMF and SEP.

We would appreciate if you could looks at these documents before our meeting on Monday.

Let us know if you have any questions.

Best, Jelena

[External]